Not finding it? Sign in to also search OpenAlex live.
-
Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapy2021 European Journal Of Haematology article Medicine Chronic Myeloid Leukemia Treatments Open access
Jörge E. Cortes, Hagop M. Kantarjian, Michael J. Mauro, Fiona An, Sonja Nick, Eric P. Leip, +2 more
15citations -
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Andreas Hochhaus, Susanne Saußele, François‐Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, +1 more
1citations -
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia2025 Leukemia & lymphoma/Leukemia and lymphoma article Medicine Acute Lymphoblastic Leukemia research Open access
Fabian Lang, Andreas Voß, Guido Kobbe, Christian Junghanß, Joachim Beck, Andreas Viardot, +10 more
1citations -
Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Roman Pfeifer, Giovanni Cazzaniga, Vincent H. J. van der Velden, J M Cayuela, Beat W. Schäfer, Orietta Spinelli, +32 more
1citations -
Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm2020 Annals of Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
David C. A. Molitor, Peter Boor, Andreas Buneß, Rebekka K. Schneider, Lino Lars Teichmann, Ruth-Miriam Körber, +3 more
18citations -
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
Gianantonio Rosti, Tim H. Brümmendorf, Bjørn Tore Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti, Carlo B Gambacorti-Passerini, +6 more
10citations -
NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms2025 Nature Communications article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Ruth-Miriam Koerber, Calvin Krollmann, Kevin Cieslak, Elisabeth Tregel, M. Saenz, Tim H. Brümmendorf, +9 more
8citations -
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms2024 Frontiers in Immunology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Tobias Idor Boklund, Johanne Gudmand‐Hoeyer, Morten Kranker Larsen, Trine Alma Knudsen, Christina Schjellerup Eickhardt‐Dalbøge, Vibe Skov, +5 more
8citations -
Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
Jörge E. Cortes, Philipp D. le Coutre, Carlo B Gambacorti-Passerini, Henrik Hjorth‐Hansen, Pia Raanani, Valentín García‐Gutiérrez, +5 more
5citations